Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00447122 · ClinicalTrials.gov registry record · Phase 1
BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer
A Phase 1 study, sponsored by Brown University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00447122 is a Phase 1 study that was terminated before completion, run by Brown University. The registered enrollment target is 25 participants.
The verdict
NCT00447122, a Phase 1 study, was terminated before completion, sponsored by Brown University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
Phase I study of lapatinib and gemcitabine for patients with metastatic pancreaticobiliary cancer.
Interventions
- DRUG Gemcitabine 1000mg/m2 30 minutes
- DRUG Lapatinib 1000mg/d
- DRUG Lapatinib 1500mg/d
- DRUG Gemcitabine 1000mg/m2 100minutes
- DRUG Oxaliplatin 100mg/m2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2007-03 |
| Est. Completion | 2008-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00447122
The ClinicalTrials.gov registry entry for NCT00447122 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brown University, which has 231 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Gemcitabine 1000mg/m2 30 minutes is the first listed.
NCT00447122 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00447122 about?
NCT00447122 is a clinical study titled "BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer". Phase I study of lapatinib and gemcitabine for patients with metastatic pancreaticobiliary cancer.
What is the current status of trial NCT00447122?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2007-03. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00447122?
The interventions under investigation include: Gemcitabine 1000mg/m2 30 minutes (DRUG), Lapatinib 1000mg/d (DRUG), Lapatinib 1500mg/d (DRUG), Gemcitabine 1000mg/m2 100minutes (DRUG), Oxaliplatin 100mg/m2 (DRUG).
Who is sponsoring clinical trial NCT00447122?
This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.